Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarkers Potentially Diagnose Alzheimer's Disease Early

By LabMedica International staff writers
Posted on 12 Jun 2013
A blood test that offers promise as a way to detect Alzheimer's disease (AD) at its earliest onset has been evaluated. More...


The test has the potential to detect distinct metabolic signatures in blood plasma that are synonymous with the disease years before patients begin showing cognitive decline.

Scientists at the Mayo Clinic (Rochester, Minnesota, USA) analyzed cerebrospinal fluid and plasma samples from 45 people in the Mayo Clinic Alzheimer's Disease Center, 15 with no cognitive decline, 15 with mild cognitive impairment (MCI) and 15 with AD. The team applied a liquid chromatography/mass spectrometry-based nontargeted metabolomics approach to determine global metabolic changes in plasma and cerebrospinal fluid (CSF) from the same individuals with different AD severity.

Metabolomics assesses what is happening in the body at a given time and at a fine level of detail, giving scientists insight into the cellular processes that underlie a disease. In this case, the metabolomic profiles showed changes in metabolites related to mitochondrial function and energy metabolism, further confirming that altered mitochondrial energetics is at the root of the disease process.

Metabolic profiling detected a total of significantly altered 342 plasma and 351 CSF metabolites, of which 22% were identified. Based on the changes of more than 150 metabolites, they found 23 altered canonical pathways in plasma and 20 in CSF in MCI compared with cognitively normal (CN) individuals with a false discovery rate of less than 0.05. The time-of-flight mass spectrometry was performed using the Agilent 6220 (Agilent Technologies, Santa Clara, CA, USA).

Eugenia Trushina, PhD, a Mayo Clinic pharmacologist, and lead author of the study, said, “We want to use these biomarkers to diagnose the Alzheimer's disease before symptoms appear, which can be decades before people start exhibiting memory loss. The earlier we can detect the disease, the better treatment options we will be able to offer." Dr. Trushina hopes that the identified changes in the metabolic pathways could lead to a panel of biomarkers, which can eventually be used on a larger scale for early diagnosis, and monitoring of Alzheimer's progression. The study was published on May 20, 2013, in the journal Public Library of Science ONE.

Related Links:

Mayo Clinic

Agilent Technologies



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.